Closure of Trading Window - For declaration of unaudited financial results for the quarter ended on December 31, 2025
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has informed the stock exchanges that its trading window will be closed for all Directors, Designated Persons, and Connected Persons starting January 1, 2026. The closure will remain in effect until 48 hours after the company publicly announces its unaudited financial results (both standalone and consolidated) for the quarter and nine months ended December 31, 2025. The Board meeting date to approve these Q3 FY26 results will be communicated separately. This is a standard compliance filing under the company's insider trading code.
This is a routine regulatory filing with no direct impact on shareholders or the stock price. Investors can expect the Q3 FY26 earnings announcement in the coming weeks, and expect quiet period behavior from company insiders during this window.